Do GLP-1–Based Therapies Increase Cancer Risk?
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
Cases of pancreatitis have been de-scribed in connection with the useof exenatide (1), liraglutide (2) and other glucagon-like peptide (GLP)-1 re-ceptor agonists. From these findings, the following hypothesis has been generated: stimulating the GLP-1 receptor with re-spective agonists has a potential to cause pancreatitis, perhaps chronic pancreati-tis, and in the long term, potentially even pancreatic cancer (3–5). Further-more, in rodents like mice and rats, stim-ulating the GLP-1 receptor raises cAMP in thyroid C cells, initiates the release of cal-citonin, and upon longer-term exposure, is accompanied by C-cell proliferation and the formation of C-cell adenomas
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, there is evidence that GLP-1 analogues increase the risk of medullary thyroid cancer, which is a cause for concern.268”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [268]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“For the purpose of this review, GLP-1–based therapies are GLP-1 receptor agonists such as exenatide, liraglutide, and others or dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin (8).”
BackgroundSelf-citationVincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62307-0 · Cited by 2,586
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502 · cited 1×
“It takes another 7 years (approximately) for such cells to develop subclones with metastatic capacity and another 3 years (approximately) before the disease will be diagnosed due to clinical symptoms and a clinically apparent primary tumor accompanied by metastases (13).”
BackgroundUnder-Reporting of Adverse Drug Reactions: A Systematic Review
Hazell, L., & Shakir, S. A. W. (2006) · Drug Safety · doi:10.2165/00002018-200629050-00003 · Cited by 1,931
Pancreatitis and the Risk of Pancreatic Cancer
Lowenfels, A. B., Maisonneuve, P., Cavallini, G., Ammann, R. W., Lankisch, P. G., Andersen, J. R., Dimagno, E. P., Andren-Sandberg, A., & Domellof, L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305203282001 · Cited by 1,757
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 8×
“(3), we looked at subcategories of malignant disease entities.”
BackgroundMethodInfluentialBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 5×
“C-cell disease ranges from C-cell hyperplasia to C-cell adenoma and medullary carcinoma (6).”
BackgroundInfluentialDeterminants of Under-Reporting of Adverse Drug Reactions: A Systematic Review
Lopez-Gonzalez, E., Herdeiro, M. T., & Figueiras, A. (2009) · Drug Safety · doi:10.2165/00002018-200932010-00002 · Cited by 574
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 1×
“In mice and rats, a once-daily injection of liraglutide, a GLP-1 receptor agonist that has an approximate half-life of 13 h, leads to permanently elevated circulating drug concentrations (32,33) and increased rate of C-cell abnormalities in both mice and rats, with some animals developing C-cell carcinomas, especially…”
Background
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“When GLP-1 RAs were introduced as novel agents to treat type 2 diabetes, there was uncertainty about several potential adverse effects such as acute pancreatitis, pancreatic cancer, and thyroid cancer [102,103].”
BackgroundSelf-citationBethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30412-6 · Cited by 599
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
“Detailed discussions of pancreatitis potentially induced by DPP-4 inhibitors have been published [51,52].”
BackgroundSelf-citationGraaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
“Acute pancreatitis may potentially progress to chronic pancreatitis and ultimately develop pancreatic cancer (Yachida et al., 2010; Nauck and Friedrich, 2013).”
BackgroundMethod
Metadata
- Authors
- Nauck, M. A., & Friedrich, N.
- Affiliations
- Diabeteszentrum Bad Lauterberg (DE)
- Universität Greifswald (DE)
- Corresponding author
- Friedrich, Nele
- ORCID
- Nauck, Michael A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-07-17
- Volume
- 36
- Issue
- Supplement_2
- Pages
- S245-S252
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3920789
- OpenAlex
- W2158762809
- Cited by
- 145
- References
- 56
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 10 · 2023: 8 · 2022: 10 · 2021: 12 · 2020: 10 · 2019: 8 · 2018: 7 · 2017: 17 · 2016: 12 · 2015: 13 · 2014: 17 · 2013: 2
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- GLP-1 receptor agonists, exenatide, liraglutide, pancreatitis, chronic pancreatitis, pancreatic cancer, thyroid C cells, calcitonin, cAMP signaling, cancer risk
- MeSH terms
- Animals, Drug Therapy, Combination, Humans, Hypoglycemic Agents, Pancreatic Neoplasms, Pancreatitis, Risk Factors, Thyroid Neoplasms, Glucagon-Like Peptide 1, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.